- Samsung Biologics presented a three-pillar expansion strategy at the 2026 J.P. Morgan Healthcare Conference, focusing on manufacturing capacity, portfolio breadth, and global footprint to become a global top-tier CDMO.
- The company’s global manufacturing capacity will reach 845,000 litres following the completion of its $280 million acquisition of GSK’s Rockville, Maryland facility, with total capacity across Songdo Plants 1-5 standing at 785,000 litres.
Samsung Biologics has announced a three-pillar expansion strategy to establish itself as a global top-tier contract development and manufacturing organisation. Chief executive John Rim presented the company’s achievements and growth strategy at the 2026 J.P. Morgan Healthcare Conference in San Francisco on Tuesday.
The company has expanded its global manufacturing capacity to 845,000 litres. This includes 785,000 litres across its Plants 1 through 5 in Songdo, Incheon, South Korea, following the full operation of its 180,000-litre Plant 5 in April 2025 and the addition of 1,000-litre bioreactors at Plant 2. The acquisition of a biologics manufacturing facility in Rockville, Maryland, announced last month, adds a further 60,000 litres and provides Samsung Biologics with its first production base in the United States.
Rim highlighted the completion of the company’s spin-off as a key achievement. Samsung Biologics separated its biosimilar investment business into Samsung Epis Holdings, with the proposal approved with 99.9 per cent support at an extraordinary shareholders’ meeting in October and completed in November. “With this spin-off, Samsung Biologics has become a pure-play CDMO,” Rim said. “It removes business-related risks and establishes a structure that allows us to focus fully on strengthening our core CDMO competitiveness.”
The company has secured a site for its third Bio Campus, which will support production of antibody-drug conjugates, antibody vaccines, and cell and gene therapies. Samsung Biologics also launched a Samsung Organoids service and outlined plans to strengthen its portfolio by integrating research and development through commercial production. The company is reviewing construction of Plant 6 at its second Bio Campus and seeking additional expansion opportunities at the Rockville site.
Samsung Biologics plans to apply its proprietary ExellenS manufacturing system across all facilities. Unveiled in October last year, ExellenS is the company’s CDMO service brand that embraces equivalency and speed as core values to supply consistently high-quality medicines to clients quickly and efficiently.
Rim said the company will continue to pursue its three-pillar expansion strategy in 2026, with key priorities including increasing manufacturing capacity, strengthening end-to-end contract research, development and manufacturing services, and enhancing customer satisfaction through further expansion of global sites.
